From Alphastreet - Earnings Decoded. Market Intelligence Delivered · Newsdesk · · 1m 50s
MiniMed's growth story hides a cash flow problem
Nine analysts raised targets, but the diabetes tech company faces margin pressure and Medtronic separation risks.
In brief
Nine analysts raised targets, but the diabetes tech company faces margin pressure and Medtronic separation risks. MiniMed is growing fast, but investors need to watch whether it can turn that growth into real cash flow as it splits from Medtronic. Originally reported by Alphastreet - Earnings Decoded. Market…
MiniMed posts strong sales growth
The diabetes tech company reported $843 million in Q1 fiscal 2027 sales, up 15.8% year-over-year. U.S. revenue grew 13.1% while international markets expanded 16.9%.
CGM and pump sales accelerate
Continuous glucose monitoring sales jumped 19.9% to $431 million, while insulin pump sales grew 21.5% to $144 million. The CGM attachment rate hit 69%, showing strong ecosystem adoption.
International markets now lead revenue
International sales contributed $603 million, or 71.5% of total revenue, growing 18.1% year-over-year. The Simplera sensor and Instinct launch fueled expansion outside the U.S.
Margin squeeze threatens profitability
Gross margin fell to 55.1% from 56.6% as Simplera sensors, which carry lower margins, make up a bigger share of sales. Management calls it temporary, but it offsets revenue gains.
Cash flow still lags despite recovery
Operating cash flow improved to negative $49 million from negative $141 million, but MiniMed holds only $207 million in cash against significant liabilities. The company is not yet cash-generative.
Medtronic spinoff begins this month
Medtronic owns 89.86% of MiniMed and launched an exchange offer on September 14, 2026, to split off at least 80.1% of shares to Medtronic shareholders on a tax-free basis. The offer expires October 9, 2026.
Analysts raise targets, but risks remain
Nine analysts raised price targets to a median of $23.00 with a Moderate Buy rating. But the bull case requires three things to work: margin recovery, sustained growth converting to cash flow, and a smooth Medtronic separation.
In short
MiniMed is growing fast, but investors need to watch whether it can turn that growth into real cash flow as it splits from Medtronic.
